Rimonabant (SR141716): Selective CB1 Antagonist for Cannabinoid Research

Executive Summary: Rimonabant (SR141716) is a small molecule antagonist with high affinity (Ki = 1.8 nM) for the CB1 receptor and over 285-fold selectivity against CB2 (Ki = 514 nM), making it a gold standard tool for dissecting endocannabinoid signaling (APExBIO product data). It competitively inhibits CB1-mediated pathways involved in appetite regulation and energy balance, resulting in robust appetite suppression in diverse animal models (sex-differentiated rodent models). Rimonabant is highly soluble in DMSO (≥23.19 mg/mL) and ethanol (≥57.1 mg/mL), but insoluble in water, requiring careful solvent selection for experiments. It also demonstrates cell-type-specific effects, including induction of apoptosis in keratinocytes and immune modulation in human PBMCs. The compound is a reference agent in studies on cannabinoid withdrawal, appetite, obesity, and inflammation, and is supplied by APExBIO as the B1429 reagent.

Biological Rationale

The endocannabinoid system is a conserved signaling network involving CB1 and CB2 receptors, with CB1 being predominantly expressed in the central nervous system and regulating appetite, reward, and energy homeostasis. Dysregulation of CB1 signaling is implicated in obesity, addiction, and metabolic diseases (APExBIO). Rimonabant (SR141716) was developed to selectively inhibit CB1, enabling precise modulation of this pathway for research purposes. Notably, CB1 antagonism allows for detailed studies on the physiological and behavioral consequences of blocking endocannabinoid activity, especially in models of overnutrition and cannabinoid dependence (rat withdrawal models).

Mechanism of Action of Rimonabant (SR141716)

Rimonabant (SR141716) acts as a competitive antagonist at the CB1 receptor, binding with high affinity (Ki = 1.8 nM) and preventing endogenous or synthetic agonists from activating the receptor (product specification). Its selectivity for CB1 over CB2 is over 285-fold, minimizing off-target effects (APExBIO). In vitro, Rimonabant reduces keratinocyte viability through induction of apoptosis and modulates immune cell populations. In vivo, it inhibits CB1-mediated signaling in the hypothalamus and other brain regions, leading to decreased appetite and food intake in rodent and primate models. In the context of cannabinoid withdrawal, Rimonabant precipitates withdrawal symptoms by acutely blocking CB1 signaling after chronic agonist exposure (evidence from WIN 55,212-2 studies).

Evidence & Benchmarks

• Rimonabant binds to CB1 with a Ki of 1.8 nM, providing high-affinity and selective inhibition (APExBIO).
• CB2 binding is over 285 times weaker (Ki = 514 nM), minimizing CB2-mediated effects (APExBIO).
• In rat models, Rimonabant at 3 mg/kg precipitated withdrawal symptoms in females and at 10 mg/kg in males after chronic exposure to WIN 55,212-2, confirming its utility for modeling dependence and withdrawal (sex-differentiated withdrawal analysis).
• Topical application in mice reduces inflammatory edema and leukocyte infiltration, demonstrating anti-inflammatory properties in vivo (APExBIO).
• In vitro, Rimonabant reduces viability of keratinocyte cell lines via apoptosis and alters PBMC populations, supporting its role as a mechanistic probe in cell signaling research (assay guidance).
• Compared to cannabinoid agonists like WIN 55,212-2, Rimonabant does not induce psychotropic or locomotor suppression at moderate doses in female rats, but higher doses may reduce locomotion in males (detailed behavioral study).

This article extends the analysis in "Precision CB1 Antagonism in Translational Research" by providing updated sex-specific withdrawal modeling and solvent handling guidance, clarifying protocol nuances for experimental reproducibility. Unlike previous cell assay-focused pieces, this article synthesizes both in vivo and in vitro applications, enhancing translational relevance.

Applications, Limits & Misconceptions

Rimonabant (SR141716) is primarily used in:

• Endocannabinoid system modulation studies, including appetite control and obesity research.
• Precipitation of cannabinoid withdrawal in animal models, enabling quantification of withdrawal severity and sex differences (WIN 55,212-2 withdrawal study).
• As a benchmark compound for CB1 inhibition in cell viability, proliferation, and cytotoxicity assays (assay protocols).
• Translational research on obesity and inflammatory processes.

Common Pitfalls or Misconceptions

• Rimonabant is not a CB2-selective agent; its use in CB2-dominant systems may produce weak or negligible effects (Ki = 514 nM for CB2).
• It is insoluble in water; direct aqueous application leads to precipitation and loss of activity (solubility data).
• High-dose or chronic use in vivo may produce off-target effects or toxicity, especially outside CB1-rich tissues.
• Withdrawal symptoms precipitated by Rimonabant are context-dependent and require prior cannabinoid agonist exposure; it does not induce withdrawal in naïve animals (rodent withdrawal study).
• Clinical use in humans was discontinued due to psychiatric side effects, restricting its use to preclinical and mechanistic research.

Workflow Integration & Parameters

• Solvent preparation: Dissolve Rimonabant (SR141716) at ≥23.19 mg/mL in DMSO or ≥57.1 mg/mL in ethanol; do not use water as a solvent (product recommendation).
• Storage: Store powder at -20°C; avoid long-term storage of solutions to preserve stability.
• In vivo dosing: In rats, use 3 mg/kg (females) or 10 mg/kg (males) to precipitate withdrawal after chronic cannabinoid agonist exposure; titrate according to species and endpoint (WIN model).
• Cell assays: Use validated concentrations in the low nanomolar to micromolar range, depending on cell line and endpoint; refer to cell viability protocols for guidance.
• Withdrawal modeling: Administer after chronic exposure to a CB1/CB2 agonist (e.g., WIN 55,212-2) to elicit measurable somatic and anxiety-like behaviors.

Conclusion & Outlook

Rimonabant (SR141716) remains a foundational tool in cannabinoid research due to its high selectivity, robust antagonist profile, and well-characterized pharmacology. It enables precise modeling of appetite regulation, obesity, and withdrawal syndromes in preclinical studies. Sex differences in withdrawal responses, as elucidated in recent rodent models, underscore the need for stratified study designs (detailed withdrawal study). While its clinical use is limited, Rimonabant continues to inform mechanistic understanding of the endocannabinoid system and supports the development of new anti-obesity and anti-addiction strategies. For validated, reproducible results, APExBIO's Rimonabant (SR141716) (SKU B1429) offers reliable quality and documentation for research applications. For more practical guidance, see protocol comparisons in companion translational research articles.